The following consensus is up to date for Dr. Martens as at 28 March 2024
| FY23A Year ending March 2023 (Reported) |
FY24E Year ending March 2024 |
FY25E Year ending March 2025 |
FY26E Year ending March 2026 |
|
|---|---|---|---|---|
| Revenue (£m) | £1,000.3 | £882.1 | £905.2 | £969.6 |
| EBITDA (£m) | £245.0 | £196.9 | £213.4 | £235.0 |
| PBT (£m) | £159.4 | £97.4 | £107.9 | £124.5 |
| EPS | 12.9p | 7.4p | 8.3p | 9.6p |
| DPS | 5.8p | 4.8p | 4.9p | 5.1p |
The above consensus is the mean average of forecasts gathered from 8 out of 9 covering sell-side analysts
Legal disclaimer
These financial forecasts are not prepared nor endorsed by Dr. Martens in any way. Dr. Martens has no current or pending duty to verify any individual estimates and assumes no responsibility to update, revise or otherwise comment on any of the information contained in these forecasts. It should be noted that financial forecasts are, by definition, forward looking, and are therefore subject to various risks and uncertainties which are subject to change at any time.
